Compare Bank of Montreal (BMO) vs Mesoblast Limited (MESO) Price & Performance

Bank of MontrealTrade

Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Bank of Montreal vs Mesoblast Limited — how do they compare? Bank of Montreal trades at $180.98 (market cap $125.53B), while Mesoblast Limited trades at $17.69 (market cap $2.12B). The key difference: Bank of Montreal is far larger — about 59.2× Mesoblast Limited's market cap, and Bank of Montreal pays a 2.74% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

	BMO	MESO
Market Cap	$125.53B	$2.12B
Sector	Financials	Technology
52-Week High	$180.86	$20.96
52-Week Low	$110.44	$10.96
Dividend Yield	2.74%	—
Enterprise Value	—	$2.13B

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bank of Montreal

BMO trades at $178.69, down 0.15% today, with a bullish technical signal supported by moving averages and key resistance at $180. The company reported strong Q1 2026 earnings of $2.68 per share, beating estimates, and maintains a solid net income margin of 25.92%. Recent acquisitions and dividend increases highlight strategic growth, while analyst sentiment is balanced with 44% buy ratings.

Outlook remains positive driven by consistent earnings beats and expansion in metals & mining banking. Risks include valuation above historical norms with a P/E of 19.48 and exposure to interest rate sensitivity. The stock offers a compelling dividend yield but faces macroeconomic headwinds that could pressure future performance.

Mesoblast Limited

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

BMO

KKR leads major $400M financing deal, maintains strong outlook despite price target cutGordon Thompson · 16 hours agoBullish Alterra IOS secures $400M refinancing for 99 industrial outdoor storage sites across 27 statesGlobeNewsWire · 1 day agoBullish View details →

MESO

Mesoblast completes treatment of 300 patients in Phase 3 trial for chronic low back pain therapy.GlobeNewsWire · 1 day agoBullish Mesoblast advances to commercial stage with FDA-approved Ryoncil and strong early revenue growth.Seeking Alpha · 4 days agoBullish View details →

About Bank of Montreal

Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.